|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Patel SG, Karlitz JJ, Yen T, Lieu CH and
Boland CR: The rising tide of early-onset colorectal cancer: A
comprehensive review of epidemiology, clinical features, biology,
risk factors, prevention, and early detection. Lancet Gastroenterol
Hepatol. 7:262–274. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen EX, Jonker DJ, Loree JM, Kennecke HF,
Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, et al:
Effect of combined immune checkpoint inhibition vs best supportive
care alone in patients with advanced colorectal cancer: The
Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 6:831–838.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hudita A, Radu IC, Galateanu B, Ginghina
O, Herman H, Balta C, Rosu M, Zaharia C, Costache M, Tanasa E, et
al: Bioinspired silk fibroin nano-delivery systems protect against
5-FU induced gastrointestinal mucositis in a mouse model and
display antitumor effects on HT-29 colorectal cancer cells in
vitro. Nanotoxicology. 15:973–994. 2021.PubMed/NCBI
|
|
5
|
Georgiou A, Stewart A, Vlachogiannis G,
Pickard L, Valeri N, Cunningham D, Whittaker SR and Banerji U: A
phospho-proteomic study of cetuximab resistance in
KRAS/NRAS/BRAF(V600) wild-type colorectal cancer. Cell Oncol
(Dordr). 44:1197–1206. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q,
Wang L, Song GB, Sheng JP and Xu B: Signaling pathways involved in
colorectal cancer: Pathogenesis and targeted therapy. Signal
Transduct Target Ther. 9:2662024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Liu M, Jafari M and Tang J: A
critical assessment of Traditional Chinese Medicine databases as a
source for drug discovery. Front Pharmacol. 15:13036932024.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sies H, Mailloux RJ and Jakob U:
Fundamentals of redox regulation in biology. Nat Rev Mol Cell Biol.
25:701–719. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Porter RJ, Arends MJ, Churchhouse AMD and
Din S: Inflammatory bowel disease-associated colorectal cancer:
Translational risks from mechanisms to medicines. J Crohns Colitis.
15:2131–2141. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu
W and Zheng Q: Natural products as anticancer agents: Current
status and future perspectives. Molecules. 27:83672022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang H, Yue GGL, Leung PC, Wong CK and Lau
CBS: A review on the molecular mechanisms, the therapeutic
treatment including the potential of herbs and natural products,
and target prediction of obesity-associated colorectal cancer.
Pharmacol Res. 175:1060312022. View Article : Google Scholar
|
|
12
|
Bu F, Tu Y, Wan Z and Tu S: Herbal
medicine and its impact on the gut microbiota in colorectal cancer.
Front Cell Infect Microbiol. 13:10960082023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ding Y and Yu Y: Therapeutic potential of
flavonoids in gastrointestinal cancer: Focus on signaling pathways
and improvement strategies (Review). Mol Med Rep. 31:1092025.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janney A, Powrie F and Mann EH:
Host-microbiota maladaptation in colorectal cancer. Nature.
585:509–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zińczuk J, Maciejczyk M, Zaręba K,
Pryczynicz A, Dymicka-Piekarska V, Kamińska J, Koper-Lenkiewicz O,
Matowicka-Karna J, Kędra B, Zalewska A and Guzińska-Ustymowicz K:
Pro-Oxidant enzymes, redox balance and oxidative damage to
proteins, lipids and DNA in colorectal cancer tissue. is oxidative
stress dependent on tumour budding and inflammatory infiltration?
Cancers (Basel). 12:16362020. View Article : Google Scholar
|
|
16
|
Monticelli S and Cejka P: DNA sensing and
repair systems unexpectedly team up against cancer. Nature.
625:457–458. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajeigbe OF, Maruf OR, Anyebe DA, Opafunso
IT, Ajayi BO and Farombi EO: 6-shogaol suppresses AOM/DSS-mediated
colorectal adenoma through its antioxidant and anti-inflammatory
effects in mice. J Food Biochem. 46:e144222022. View Article : Google Scholar
|
|
18
|
Liu C, Rokavec M, Huang Z and Hermeking H:
Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress
colorectal cancer metastasis. Cell Death Differ. 30:1771–1785.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun R, Zhang Y, Zhao X, Tang T, Cao Y,
Yang L, Tian Y, Zhang Z, Zhang P and Xu F: Temporal and spatial
metabolic shifts revealing the transition from ulcerative colitis
to colitis-associated colorectal cancer. Adv Sci (Weinh).
12:e24125512025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bardelčíková A, Šoltys J and Mojžiš J:
Oxidative stress, inflammation and colorectal cancer: An overview.
Antioxidants (Basel). 12:9012023. View Article : Google Scholar
|
|
21
|
Mandal M, Mamun MAA, Rakib A, Kumar S,
Park F, Hwang DJ, Li W, Miller DD and Singh UP: Modulation of
occludin, NF-κB, p-STAT3, and Th17 response by DJ-X-025 decreases
inflammation and ameliorates experimental colitis. Biomed
Pharmacother. 185:1179392025. View Article : Google Scholar
|
|
22
|
Li Q, Chen Y, Zhang D, Grossman J, Li L,
Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, et al:
IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in
colorectal cancer. JCI Insight. 4:e1308672019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang M, Ma Y, Yu G, Zeng B, Yang W, Huang
C, Dong Y, Tang B and Wu Z: Integration of microbiome, metabolomics
and transcriptome for in-depth understanding of berberine
attenuates AOM/DSS-induced colitis-associated colorectal cancer.
Biomed Pharmacother. 179:1172922024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burgueño JF, Fritsch J, González EE,
Landau KS, Santander AM, Fernández I, Hazime H, Davies JM,
Santaolalla R, Phillips MC, et al: Epithelial TLR4 Signaling
Activates DUOX2 to induce microbiota-driven tumorigenesis.
Gastroenterology. 160:797–808.e6. 2021. View Article : Google Scholar
|
|
25
|
Jin BR, Chung KS, Hwang S, Hwang SN, Rhee
KJ, Lee M and An HJ: Rosmarinic acid represses colitis-associated
colon cancer: A pivotal involvement of the TLR4-mediated
NF-κB-STAT3 axis. Neoplasia. 23:561–573. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hernández-Rocha C, Turpin W, Borowski K,
Stempak JM, Sabic K, Gettler K, Tastad C, Chasteau C, Korie U,
Hanna M, et al: After surgically induced remission, Ileal and
colonic mucosa-associated microbiota predicts crohn's disease
recurrence. Clin Gastroenterol Hepatol. 23:612–620.e10. 2025.
View Article : Google Scholar
|
|
27
|
Yun X, Zhang Q, Fang Y, Lv C, Chen Q, Chu
Y, Zhu Y, Wei Z, Xia Y and Dai Y: Madecassic acid alleviates
colitis-associated colorectal cancer by blocking the recruitment of
myeloid-derived suppressor cells via the inhibition of IL-17
expression in γδT17 cells. Biochem Pharmacol. 202:1151382022.
View Article : Google Scholar
|
|
28
|
Kuo IM, Lee JJ, Wang YS, Chiang HC, Huang
CC, Hsieh PJ, Han W, Ke CH, Liao ATC and Lin CS: Potential
enhancement of host immunity and anti-tumor efficacy of nanoscale
curcumin and resveratrol in colorectal cancers by modulated
electro-hyperthermia. BMC Cancer. 20:6032020. View Article : Google Scholar
|
|
29
|
Pouliquen DL, Malloci M, Boissard A, Henry
C and Guette C: Proteomes of residual tumors in curcumin-treated
rats reveal changes in microenvironment/malignant cell crosstalk in
a highly invasive model of mesothelioma. Int J Mol Sci.
23:137322022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Montalto FI and De Amicis F: Cyclin D1 in
cancer: A molecular connection for cell cycle control, adhesion and
invasion in tumor and stroma. Cells. 9:26482020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alam M, Gulzar M, Akhtar MS, Rashid S,
Zulfareen Tanuja, Shamsi A and Hassan MI:
Epigallocatechin-3-gallate therapeutic potential in human diseases:
Molecular mechanisms and clinical studies. Mol Biomed. 5:732024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ismail NI, Othman I, Abas F, H Lajis N and
Naidu R: The curcumin analogue, MS13
(1,5-Bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one), inhibits
cell proliferation and induces apoptosis in primary and metastatic
human colon cancer cells. Molecules. 25:37982020. View Article : Google Scholar
|
|
33
|
Agarwal A, Kansal V, Farooqi H, Prasad R
and Singh VK: Epigallocatechin gallate (EGCG), an active phenolic
compound of green tea, inhibits tumor growth of head and neck
cancer cells by targeting DNA hypermethylation. Biomedicines.
11:7892023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tian M, Peng S, Wang S, Li X, Li H and
Shen L: Pristimerin reduces dextran sulfate sodium-induced colitis
in mice by inhibiting microRNA-155. Int Immunopharmacol.
94:1074912021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu H, Zhang L, Hao L and Fan D:
Resveratrol inhibits colorectal cancer cell tumor property by
activating the miR-769-5p/MSI1 pathway. Mol Biotechnol.
67:1893–1907. 2025. View Article : Google Scholar
|
|
36
|
Wang Z, Dan W, Zhang N, Fang J and Yang Y:
Colorectal cancer and gut microbiota studies in China. Gut
Microbes. 15:22363642023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chattopadhyay I, Dhar R, Pethusamy K,
Seethy A, Srivastava T, Sah R, Sharma J and Karmakar S: Exploring
the role of gut microbiome in colon cancer. Appl Biochem
Biotechnol. 193:1780–1799. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu P, Wang Y, Yang G, Zhang Q, Meng L,
Xin Y and Jiang X: The role of short-chain fatty acids in
intestinal barrier function, inflammation, oxidative stress, and
colonic carcinogenesis. Pharmacol Res. 165:1054202021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su ACY, Ding X, Lau HCH, Kang X, Li Q,
Wang X, Liu Y, Jiang L, Lu Y, Liu W, et al: Lactococcus lactis
HkyuLL 10 suppresses colorectal tumourigenesis and restores gut
microbiota through its generated alpha-mannosidase. Gut.
73:1478–1488. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deng W, Xiong X, Lu M, Huang S, Luo Y,
Wang Y and Ying Y: Curcumin suppresses colorectal tumorigenesis
through restoring the gut microbiota and metabolites. BMC Cancer.
24:11412024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leong W, Huang G, Liao W, Xia W, Li X, Su
Z, Liu L, Wu Q, Wong VKW, Law BYK, et al: Traditional Patchouli
essential oil modulates the host's immune responses and gut
microbiota and exhibits potent anti-cancer effects in Apc(Min/+)
mice. Pharmacol Res. 176:1060822022. View Article : Google Scholar
|
|
42
|
Wu Z, Huang S, Li T, Li N, Han D, Zhang B,
Xu ZZ, Zhang S, Pang J, Wang S, et al: Gut microbiota from green
tea polyphenol-dosed mice improves intestinal epithelial
homeostasis and ameliorates experimental colitis. Microbiome.
9:1842021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Urošević M, Nikolić L, Gajić I, Nikolić V,
Dinić A and Miljković V: Curcumin: biological activities and modern
pharmaceutical forms. Antibiotics (Basel). 11:1352022. View Article : Google Scholar
|
|
44
|
Weng W and Goel A: Curcumin and colorectal
cancer: An update and current perspective on this natural medicine.
Semin Cancer Biol. 80:73–86. 2022. View Article : Google Scholar
|
|
45
|
López-Gómez L and Uranga JA: Polyphenols
in the prevention and treatment of colorectal cancer: A systematic
review of clinical evidence. Nutrients. 16:27352024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Neira M, Mena C, Torres K and Simón L: The
potential benefits of curcumin-enriched diets for adults with
colorectal cancer: A systematic review. Antioxidants (Basel).
14:3882025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khan S, Karmokar A, Howells L, Britton RG,
Parrott E, Palacios-Gallego R, Tufarelli C, Cai H, Higgins J,
Sylvius N, et al: An old spice with new tricks: Curcumin targets
adenoma and colorectal cancer stem-like cells associated with poor
survival outcomes. Cancer Lett. 629:2178852025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ming T, Lei J, Peng Y, Wang M, Liang Y,
Tang S, Tao Q, Wang M, Tang X, He Z, et al: Curcumin suppresses
colorectal cancer by induction of ferroptosis via regulation of p53
and solute carrier family 7 member 11/glutathione/glutathione
peroxidase 4 signaling axis. Phytother Res. 38:3954–3972. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chuang HY, Chan HW and Shih KC:
Suppression of colorectal cancer growth: Interplay between curcumin
and metformin through DMT1 downregulation and ROS-mediated
pathways. Biofactors. 51:e21372025. View Article : Google Scholar
|
|
50
|
Li D, Cao D, Cui Y, Sun Y, Jiang J and Cao
X: The potential of epigallocatechin gallate in the chemoprevention
and therapy of hepatocellular carcinoma. Front Pharmacol.
14:12010852023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhu W and Oteiza PI: NADPH oxidase 1: A
target in the capacity of dimeric ECG and EGCG procyanidins to
inhibit colorectal cancer cell invasion. Redox Biol. 65:1028272023.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dong J, Zheng Z, Zhou M, Wang Y, Chen J,
Cen J, Cao T, Yang T, Xu Y, Shu G, et al: EGCG-LYS Fibrils-Mediated
CircMAP2K2 silencing decreases the proliferation and metastasis
ability of gastric cancer cells in vitro and in vivo. Adv Sci
(Weinh). 10:e23040752023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guan Y, Wu Q, Li M, Chen D, Su J, Zuo L,
Zhu B and Li Y: Epigallocatechin-3-gallate Induced HepG2 Cells
Apoptosis through ROSmediated AKT/JNK and p53 signaling pathway.
Curr Cancer Drug Targets. 23:447–460. 2023. View Article : Google Scholar
|
|
54
|
Suetsugu F, Tadokoro T, Fujita K, Fujihara
S, Sasaki K, Omayu E, Nakatani K, Koyama Y, Kozuka K, Matsui T, et
al: Antitumor effects of epigallocatechin-3-gallate on colorectal
cancer: An in vitro and in vivo study. Anticancer Res.
45:2937–2947. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang Z, Wang M, Huang J, Lin M and Wei P:
Dichotomic role of low-concentration EGCG in the oxaliplatin
sensitivity of colorectal cancer cells. Dokl Biochem Biophys.
515:29–35. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yi J, Ye Z, Xu H, Zhang H, Cao H, Li X,
Wang T, Dong C, Du Y, Dong S and Zhou W: EGCG targeting STAT3
transcriptionally represses PLXNC1 to inhibit M2 polarization
mediated by gastric cancer cell-derived exosomal miR-92b-5p.
Phytomedicine. 135:1561372024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu SX, Xiong RG, Huang SY, Zhou DD,
Saimaiti A, Zhao CN, Shang A, Zhang YJ, Gan RY and Li HB: Effects
and mechanisms of resveratrol for prevention and management of
cancers: An updated review. Crit Rev Food Sci Nutr. 63:12422–12440.
2023. View Article : Google Scholar
|
|
58
|
Brockmueller A, Shayan P and Shakibaei M:
Evidence that β1-integrin is required for the anti-viability and
anti-proliferative effect of resveratrol in CRC cells. Int J Mol
Sci. 23:47142022. View Article : Google Scholar
|
|
59
|
Brockmueller A, Buhrmann C, Shayan P and
Shakibaei M: Resveratrol induces apoptosis by modulating the
reciprocal crosstalk between p53 and Sirt-1 in the CRC tumor
microenvironment. Front Immunol. 14:12255302023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dariya B, Girish BP, Merchant N, Srilatha
M and Nagaraju GP: Resveratrol: Biology, metabolism, and
detrimental role on the tumor microenvironment of colorectal
cancer. Nutr Rev. 82:1420–1436. 2024. View Article : Google Scholar
|
|
61
|
Chen S, Tamaki N, Kudo Y, Tsunematsu T,
Miki K, Ishimaru N and Ito HO: Protective effects of resveratrol
against 5-fluorouracil-induced oxidative stress and inflammatory
responses in human keratinocytes. J Clin Biochem Nutr. 69:238–246.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Choi CY, Lim SC, Lee TB and Han SI:
Molecular basis of resveratrol-induced resensitization of acquired
drug-resistant cancer cells. Nutrients. 14:6992022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Recalde MD, Miguel CA, Noya-Riobó MV,
González SL, Villar MJ and Coronel MF: Resveratrol exerts
anti-oxidant and anti-inflammatory actions and prevents
oxaliplatin-induced mechanical and thermal allodynia. Brain Res.
1748:1470792020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Motawea MH, Abd Elmaksoud HA, Elharrif MG,
Desoky AAE and Ibrahimi A: Evaluation of anti-inflammatory and
antioxidant profile of oleuropein in experimentally induced
ulcerative colitis. Int J Mol Cell Med. 9:224–233. 2020.PubMed/NCBI
|
|
65
|
Sokal-Dembowska A, Jarmakiewicz-Czaja S
and Filip R: Flavonoids and their role in preventing the
development and progression of MAFLD by modifying the microbiota.
Int J Mol Sci. 25:111872024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yang B, Bai H, Sa Y, Zhu P and Liu P:
Inhibiting EMT, stemness and cell cycle involved in
baicalin-induced growth inhibition and apoptosis in colorectal
cancer cells. J Cancer. 11:2303–2317. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang J, Lei H, Hu X and Dong W:
Hesperetin ameliorates DSS-induced colitis by maintaining the
epithelial barrier via blocking RIPK3/MLKL necroptosis signaling.
Eur J Pharmacol. 873:1729922020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vukelić I, Detel D, Batičić L, Potočnjak I
and Domitrović R: Luteolin ameliorates experimental colitis in mice
through ERK-mediated suppression of inflammation, apoptosis and
autophagy. Food Chem Toxicol. 145:1116802020. View Article : Google Scholar
|
|
69
|
Panda SK, Peng V, Sudan R, Ulezko Antonova
A, Di Luccia B, Ohara TE, Fachi JL, Grajales-Reyes GE, Jaeger N,
Trsan T, et al: Repression of the aryl-hydrocarbon receptor
prevents oxidative stress and ferroptosis of intestinal
intraepithelial lymphocytes. Immunity. 56:797–812.e4. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wu Q, Luo Y, Lu H, Xie T, Hu Z, Chu Z and
Luo F: The potential role of vitamin E and the mechanism in the
prevention and treatment of inflammatory bowel disease. Foods.
13:8982024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tao S, Ren Z, Yang Z, Duan S, Wan Z, Huang
J, Liu C and Wei G: Effects of different molecular weight
polysaccharides from dendrobium officinale kimura & migo on
human colorectal cancer and transcriptome analysis of
differentially expressed genes. Front Pharmacol. 12:7044862021.
View Article : Google Scholar
|
|
72
|
Cao Q, Zhou R, Guo S, Meng K, Yang X, Liu
M, Ma B, Su C and Duan X: PLGA-Astragalus polysaccharide
nanovaccines exert therapeutic effect in colorectal cancer. Int J
Nanomedicine. 19:9437–9458. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li Q, Zhang C, Xu G, Shang X, Nan X, Li Y,
Liu J, Hong Y, Wang Q and Peng G: Astragalus polysaccharide
ameliorates CD8(+) T cell dysfunction through STAT3/Gal-3/LAG3
pathway in inflammation-induced colorectal cancer. Biomed
Pharmacother. 171:1161722024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cheng H, Liu J, Zhang D, Wang J, Tan Y,
Feng W and Peng C: Ginsenoside Rg1 alleviates acute ulcerative
colitis by modulating gut microbiota and microbial tryptophan
metabolism. Front Immunol. 13:8176002022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yang R, Gao W, Wang Z, Jian H, Peng L, Yu
X, Xue P, Peng W, Li K and Zeng P: Polyphyllin I induced
ferroptosis to suppress the progression of hepatocellular carcinoma
through activation of the mitochondrial dysfunction via
Nrf2/HO-1/GPX4 axis. Phytomedicine. 122:1551352024. View Article : Google Scholar
|
|
76
|
Li JK, Sun HT, Jiang XL, Chen YF, Zhang Z,
Wang Y, Chen WQ, Zhang Z, Sze SCW, Zhu PL and Yung KKL: Polyphyllin
II induces protective autophagy and apoptosis via Inhibiting
PI3K/AKT/mTOR and STAT3 signaling in colorectal cancer cells. Int J
Mol Sci. 23:118902022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J,
Tian Y, Wen Y and Chen T: Berberine and health outcomes: An
umbrella review. Phytother Res. 37:2051–2066. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yan S, Chang J, Hao X, Liu J, Tan X, Geng
Z and Wang Z: Berberine regulates short-chain fatty acid metabolism
and alleviates the colitis-associated colorectal tumorigenesis
through remodeling intestinal flora. Phytomedicine. 102:1542172022.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wu X, Chen X, Liu H, He ZW, Wang Z, Wei
LJ, Wang WY, Zhong S, He Q, Zhang Z, et al: Rescuing Dicer
expression in inflamed colon tissues alleviates colitis and
prevents colitis-associated tumorigenesis. Theranostics.
10:5749–5762. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wang Q, Zhao X, Jiang Y, Jin B and Wang L:
Functions of representative terpenoids and their biosynthesis
mechanisms in medicinal plants. Biomolecules. 13:17252023.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lima DAN, Pelegrini BB, Uechi FAA, Varago
RC, Pimenta BB, Kaneshima AMS, Kaneshima EN, Souza PDC, Pedroso RB,
Silveira TGV and Becker TCA: Evaluation of antineoplasic activity
of zingiber officinale essential oil in the colorectal region of
wistar rats. Asian Pac J Cancer Prev. 21:2141–2147. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chen H, Tang X, Liu T, Jing L and Wu J:
Zingiberene inhibits in vitro and in vivo human colon cancer cell
growth via autophagy induction, suppression of PI3K/AKT/mTOR
Pathway and caspase 2 deactivation. J Buon. 24:1470–1475.
2019.PubMed/NCBI
|
|
83
|
Qi H, Zhang X, Liu H, Han M, Tang X, Qu S,
Wang X and Yang Y: Shikonin induced apoptosis mediated by
endoplasmic reticulum stress in colorectal cancer cells. J Cancer.
13:243–252. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang Y, Pu W, Bousquenaud M, Cattin S,
Zaric J, Sun LK and Rüegg C: Emodin inhibits inflammation,
carcinogenesis, and cancer progression in the AOM/DSS model of
colitis-associated intestinal tumorigenesis. Front Oncol.
10:5646742021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Carroll RE, Benya RV, Turgeon DK, Vareed
S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C,
Meyskens FL Jr and Brenner DE: Phase IIa clinical trial of curcumin
for the prevention of colorectal neoplasia. Cancer Prev Res
(Phila). 4:354–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cruz-Correa M, Shoskes DA, Sanchez P, Zhao
R, Hylind LM, Wexner SD and Giardiello FM: Combination treatment
with curcumin and quercetin of adenomas in familial adenomatous
polyposis. Clin Gastroenterol Hepatol. 4:1035–1038. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Cruz-Correa M, Hylind LM, Marrero JH,
Zahurak ML, Murray-Stewart T, Casero RA Jr, Montgomery EA,
Iacobuzio-Donahue C, Brosens LA, Offerhaus GJ, et al: Efficacy and
safety of curcumin in treatment of intestinal adenomas in patients
with familial adenomatous polyposis. Gastroenterology. 155:668–673.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Panahi Y, Saberi-Karimian M, Valizadeh O,
Behnam B, Saadat A, Jamialahmadi T, Majeed M and Sahebkar A:
Effects of curcuminoids on systemic inflammation and quality of
life in patients with colorectal cancer undergoing chemotherapy: A
randomized controlled trial. Adv Exp Med Biol. 1328:1–9. 2021.
View Article : Google Scholar
|
|
89
|
Patel KR, Brown VA, Jones DJ, Britton RG,
Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA,
et al: Clinical pharmacology of resveratrol and its metabolites in
colorectal cancer patients. Cancer Res. 70:7392–7399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Seufferlein T, Ettrich TJ, Menzler S,
Messmann H, Kleber G, Zipprich A, Frank-Gleich S, Algül H, Metter
K, Odemar F, et al: Green tea extract to prevent colorectal
adenomas, results of a randomized, placebo-controlled clinical
trial. Am J Gastroenterol. 117:884–894. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Sinicrope FA, Viggiano TR, Buttar NS, Song
LMWK, Schroeder KW, Kraichely RE, Larson MV, Sedlack RE, Kisiel JB,
Gostout CJ, et al: Randomized phase II trial of polyphenon e versus
placebo in patients at high risk of recurrent colonic neoplasia.
Cancer Prev Res (Phila). 14:573–580. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bonelli L, Puntoni M, Gatteschi B, Massa
P, Missale G, Munizzi F, Turbino L, Villanacci V, De Censi A and
Bruzzi P: Antioxidant supplement and long-term reduction of
recurrent adenomas of the large bowel. A double-blind randomized
trial. J Gastroenterol. 48:698–705. 2013. View Article : Google Scholar
|
|
93
|
Oliai Araghi S, Kiefte-de Jong JC, van
Dijk SC, Swart KMA, van Laarhoven HW, van Schoor NM, de Groot
LCPGM, Lemmens V, Stricker BH, Uitterlinden AG and van der Velde N:
Folic acid and vitamin B12 supplementation and the risk of cancer:
Long-term Follow-up of the B vitamins for the prevention of
osteoporotic fractures (B-PROOF) trial. Cancer Epidemiol Biomarkers
Prev. 28:275–282. 2019. View Article : Google Scholar
|
|
94
|
Greenberg ER, Baron JA, Tosteson TD,
Freeman DH Jr, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl
HD, Haile RW, et al: A clinical trial of antioxidant vitamins to
prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J
Med. 331:141–147. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Gaziano JM, Glynn RJ, Christen WG, Kurth
T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD and Buring
JE: Vitamins E and C in the prevention of prostate and total cancer
in men: The physicians' health study II randomized controlled
trial. JAMA. 301:52–62. 2009. View Article : Google Scholar
|
|
96
|
Wang Z, Joshi AM, Ohnaka K, Morita M,
Toyomura K, Kono S, Ueki T, Tanaka M, Kakeji Y, Maehara Y, et al:
Dietary intakes of retinol, carotenes, vitamin C, and vitamin E and
colorectal cancer risk: The Fukuoka colorectal cancer study. Nutr
Cancer. 64:798–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ng K, Nimeiri HS, McCleary NJ, Abrams TA,
Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock
AJ, et al: Effect of high-dose vs standard-dose vitamin D3
supplementation on progression-free survival among patients with
advanced or metastatic colorectal cancer: The SUNSHINE randomized
clinical trial. JAMA. 321:1370–1379. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chen YX, Gao QY, Zou TH, Wang BM, Liu SD,
Sheng JQ, Ren JL, Zou XP, Liu ZJ, Song YY, et al: Berberine versus
placebo for the prevention of recurrence of colorectal adenoma: A
multicentre, double-blinded, randomised controlled study. Lancet
Gastroenterol Hepatol. 5:267–275. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Mao Q, Min J, Zeng R, Liu H, Li H, Zhang
C, Zheng A, Lin J, Liu X and Wu M: Self-assembled traditional
Chinese nanomedicine modulating tumor immunosuppressive
microenvironment for colorectal cancer immunotherapy. Theranostics.
12:6088–6105. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ali ES, Sharker SM, Islam MT, Khan IN,
Shaw S, Rahman MA, Uddin SJ, Shill MC, Rehman S, Das N, et al:
Targeting cancer cells with nanotherapeutics and nanodiagnostics:
Current status and future perspectives. Semin Cancer Biol.
69:52–68. 2021. View Article : Google Scholar
|
|
101
|
Cheng Z, Li M, Dey R and Chen Y:
Nanomaterials for cancer therapy: Current progress and
perspectives. J Hematol Oncol. 14:852021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang Z, Ji Y, Hu N, Yu Q, Zhang X, Li J,
Wu F, Xu H, Tang Q and Li X: Ferroptosis-induced anticancer effect
of resveratrol with a biomimetic nano-delivery system in colorectal
cancer treatment. Asian J Pharm Sci. 17:751–766. 2022.PubMed/NCBI
|
|
103
|
Sun D, Zou Y, Song L, Han S, Yang H, Chu
D, Dai Y, Ma J, O'Driscoll CM, Yu Z and Guo J: A cyclodextrin-based
nanoformulation achieves co-delivery of ginsenoside Rg3 and
quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharm
Sin B. 12:378–393. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tawfik SM, Azizov S, Elmasry MR, Sharipov
M and Lee YI: Recent advances in nanomicelles delivery systems.
Nanomaterials (Basel). 11:702020. View Article : Google Scholar
|
|
105
|
Ran P, Wang W, An Z, Gao N, He Y and Wu Z:
Preparation and in vitro biological studies of photothermal
response ginsenoside CK-carboxymethyl chitosan-based prodrug
nanomicelles for synergistic therapy. Int J Biol Macromol.
316:1447472025. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhu C, Gong S, Ding J, Yu M, Ahmad E, Feng
Y and Gan Y: Supersaturated polymeric micelles for oral silybin
delivery: The role of the Soluplus-PVPVA complex. Acta Pharm Sin B.
9:107–117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Li M, Du C, Guo N, Teng Y, Meng X, Sun H,
Li S, Yu P and Galons H: Composition design and medical application
of liposomes. Eur J Med Chem. 164:640–653. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Rahman S, Cao S, Steadman KJ, Wei M and
Parekh HS: Native and β-cyclodextrin-enclosed curcumin: Entrapment
within liposomes and their in vitro cytotoxicity in lung and colon
cancer. Drug Deliv. 19:346–353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhang Y, Li Z, Huang Y, Xu Y and Zou B:
Nanotechnology and curcumin: A novel and promising approach in
digestive cancer therapy. Nanomedicine (Lond). 18:2081–2099. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bhattacharjya D and Sivalingam N:
Mechanism of 5-fluorouracil induced resistance and role of piperine
and curcumin as chemo-sensitizers in colon cancer. Naunyn
Schmiedebergs Arch Pharmacol. 397:8445–8475. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Brockmueller A, Samuel SM, Mazurakova A,
Busselberg D, Kubatka P and Shakibaei M: Curcumin, calebin A and
chemosensitization: How are they linked to colorectal cancer? Life
Sci. 318:1215042023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Suman I, Jezidzic A, Dobric D and
Domitrovic R: Differential effects of rutin and its aglycone
quercetin on cytotoxicity and chemosensitization of HCT 116 colon
cancer cells to anticancer drugs 5-fluorouracil and doxorubicin.
Biology (Basel). 14:5272025.PubMed/NCBI
|
|
113
|
Lee J, Jang CH, Kim Y, Oh J and Kim JS:
Quercetin-induced glutathione depletion sensitizes colorectal
cancer cells to oxaliplatin. Foods. 12:17332023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Deng H, Wei F, Han W, Li Y, Xu X, Zhang L
and Zhang Y: Synergistic chemotherapy and immunomodulatory effects
of Quercetin in cancer: A review. Front Immunol. 16:15479922025.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wu W, Li J, Yin Y, Zhou Y, Huang X, Cao Y,
Chen X, Zhou Y, Du J, Xu Z, et al: Rutin attenuates
ensartinib-induced hepatotoxicity by non-transcriptional regulation
of TXNIP. Cell Biol Toxicol. 40:382024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Howells LM, Iwuji COO, Irving GRB, Barber
S, Walter H, Sidat Z, Griffin-Teall N, Singh R, Foreman N, Patel
SR, et al: Curcumin combined with FOLFOX chemotherapy is safe and
tolerable in patients with metastatic colorectal cancer in a
randomized phase IIa trial. J Nutr. 149:1133–1139. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Sen K, Banerjee S and Mandal M: Dual drug
loaded liposome bearing apigenin and 5-Fluorouracil for synergistic
therapeutic efficacy in colorectal cancer. Colloids Surf B
Biointerfaces. 180:9–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Liu Y, Zhang H, Cui H, Zhang F, Zhao L,
Liu Y and Meng Q: Combined and targeted drugs delivery system for
colorectal cancer treatment: Conatumumab decorated, reactive oxygen
species sensitive irinotecan prodrug and quercetin co-loaded
nanostructured lipid carriers. Drug Deliv. 29:342–350. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Vandereyken K, Sifrim A, Thienpont B and
Voet T: Methods and applications for single-cell and spatial
multi-omics. Nat Rev Genet. 24:494–515. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lu L, Przybylla R, Shang Y, Dai M, Krohn
M, Krämer OH, Mullins CS and Linnebacher M: Microsatellite Status
and IĸBα expression levels predict sensitivity to pharmaceutical
curcumin in colorectal cancer cells. Cancers (Basel). 14:10322022.
View Article : Google Scholar
|
|
121
|
Kadosh E, Snir-Alkalay I, Venkatachalam A,
May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger
M, et al: The gut microbiome switches mutant p53 from
tumour-suppressive to oncogenic. Nature. 586:133–138. 2020.
View Article : Google Scholar : PubMed/NCBI
|
